These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 11565539)

  • 1. Phenotype and genotype expression in pseudohomozygous R2 factor V.
    Kalafatis M; Simioni P; Bernardi F
    Blood; 2001 Sep; 98(6):1988-9. PubMed ID: 11565539
    [No Abstract]   [Full Text] [Related]  

  • 2. The factor V R2 allele: risk of venous thromboembolism, factor V levels and resistance to activated protein C.
    Luddington R; Jackson A; Pannerselvam S; Brown K; Baglin T
    Thromb Haemost; 2000 Feb; 83(2):204-8. PubMed ID: 10739373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activated protein C resistance in the Japanese population due to homozygosity for the factor V R2 haplotype.
    Okada H; Toyoda Y; Takagi A; Saito H; Kojima T; Yamazaki T
    Int J Hematol; 2010 Apr; 91(3):549-50. PubMed ID: 20300981
    [No Abstract]   [Full Text] [Related]  

  • 4. Activated protein C resistance, factor V Leiden, and retinal vessel occlusion.
    Ma AD; Abrams CS
    Retina; 1998; 18(4):297-300. PubMed ID: 9730170
    [No Abstract]   [Full Text] [Related]  

  • 5. Factor V Leiden: to test or not to test, that is the debate.
    Makris M
    Blood Transfus; 2012 Jul; 10(3):255-6. PubMed ID: 22889814
    [No Abstract]   [Full Text] [Related]  

  • 6. Allelic discrimination of factor V Leiden using the GeneAmp 5700 Sequence Detection System.
    Monk SE; Duckworth AW; Farrugia J; Copplestone JA; Rule SA
    Thromb Haemost; 2002 Dec; 88(6):1071-2. PubMed ID: 12529765
    [No Abstract]   [Full Text] [Related]  

  • 7. Factor V Leiden haplotypes in two homozygotes of Asian origin.
    Rees DC; Clarke K; Martin PG; Keeling DM
    Br J Haematol; 1998 Sep; 102(5):1381-2. PubMed ID: 9753076
    [No Abstract]   [Full Text] [Related]  

  • 8. Phenotype and genotype expression in pseudohomozygous factor VLEIDEN : the need for phenotype analysis.
    Kalafatis M; Bernardi F; Simioni P; Lunghi B; Girolami A; Mann KG
    Arterioscler Thromb Vasc Biol; 1999 Feb; 19(2):336-42. PubMed ID: 9974416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ala147Thr and C+1542G polymorphisms in the TAFI gene are not asssociated with a higher risk of venous thrombosis in FV Leiden carriers.
    Morange PE; Aillaud MF; Nicaud V; Henry M; Juhan-Vague I
    Thromb Haemost; 2001 Dec; 86(6):1583-4. PubMed ID: 11776333
    [No Abstract]   [Full Text] [Related]  

  • 10. Heterogeneity of activated protein C resistance phenotype in subjects with compound heterozygosity for HR2 haplotype and FV Leiden mutation (R506Q) in factor V gene.
    Castaman G; Ruggeri M; Tosetto A; Rodeghiero F
    Thromb Haemost; 2000 Aug; 84(2):357-8. PubMed ID: 10959717
    [No Abstract]   [Full Text] [Related]  

  • 11. [Genetic analysis after allograft: prudence!].
    Billon S; Mercier B; Férec C; Abgrall JF
    Presse Med; 2000 Jul 8-15; 29(24):1353. PubMed ID: 10938691
    [No Abstract]   [Full Text] [Related]  

  • 12. Two novel factor V null mutations associated with activated protein C resistance phenotype/genotype discrepancy.
    Dargaud Y; Trzeciak MC; Meunier S; Angei C; Pellechia D; Négrier C; Vinciguerra C
    Br J Haematol; 2003 Oct; 123(2):342-5. PubMed ID: 14531918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of testing for factor V Leiden.
    Franchini M
    Blood Transfus; 2012 Jul; 10(3):257-9. PubMed ID: 22889815
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical evaluation of a functional prothrombin time-based assay for identification of factor V Leiden carriers in a group of Italian patients with venous thrombosis.
    Gessoni G; Valverde S
    Blood Coagul Fibrinolysis; 2007 Oct; 18(7):603-10. PubMed ID: 17890946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activated protein C resistance assay and factor V Leiden.
    Prüller F; Weiss EC; Raggam RB; Cervar-Zivkovic M; Renner W; Wagner J; Michaelis S; März W; Mangge H
    N Engl J Med; 2014 Aug; 371(7):685-6. PubMed ID: 25119624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interpreting results from Factor V Leiden mutation analysis: a cautionary note.
    Sinclair GD; Poon MC
    Clin Appl Thromb Hemost; 2013; 19(1):106-7. PubMed ID: 23034579
    [No Abstract]   [Full Text] [Related]  

  • 17. More on: does the factor V Asp79His (409 G/C) polymorphism influence Factor V and APC resistance levels?
    Bossone A; Margaglione M
    J Thromb Haemost; 2005 Feb; 3(2):417. PubMed ID: 15670067
    [No Abstract]   [Full Text] [Related]  

  • 18. The HR2 haplotype of factor V: effects on factor V levels, normalized activated protein C sensitivity ratios and the risk of venous thrombosis.
    de Visser MC; Guasch JF; Kamphuisen PW; Vos HL; Rosendaal FR; Bertina RM
    Thromb Haemost; 2000 Apr; 83(4):577-82. PubMed ID: 10780320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is homozygosity for the HR2 haplotype a risk factor for venous thromboembolism?
    Aras O; Hanson NQ; Tsai MY; Key NS
    Thromb Haemost; 2002 Jan; 87(1):173-4. PubMed ID: 11848451
    [No Abstract]   [Full Text] [Related]  

  • 20. Further evidence that activated protein C resistance affects protein C coagulant activity assays.
    Jennings I; Kitchen S; Cooper PC; Rimmer JE; Woods TA; Preston FE
    Thromb Haemost; 2000 Jan; 83(1):171-2. PubMed ID: 10669173
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.